Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.

Ying LiJia-Jing LuXiao-Yuan ZhongYing-Yuan YuNing YuYu WangXue-Mei YiYang-Feng DingYu-Ling Shi

Published in: Clinical, cosmetic and investigational dermatology (2022)

These results suggest that guselkumab exhibited superior drug survival, drug survival outcomes for ixekizumab and secukinumab were comparable, and significantly better than those of adalimumab in China. Preventing a loss of drug efficacy represents a primary approach to improving biologic drug survival in psoriasis patients.

Keyphrases

rheumatoid arthritis
end stage renal disease
adverse drug
newly diagnosed
chronic kidney disease
drug induced
randomized controlled trial
emergency department
study protocol
patient reported outcomes